Scholarlink

Background <p>Endometrial cancer (EC) is the predominant gynecologic malignancy in high-income countries and globally ranks as the sixth most common tumor among women, primarily influenced by hormonal factors. Recent studies have indicated a potential involvement of beta-human chorionic gonadotropin (β-hCG) in EC tumor formation and metastatic progression, expanding its traditional association beyond pregnancy. Hence, our study aimed to examine the levels of β-hCG and their correlation with a well-established tumor marker, cancer antigen (CA) 125, in EC patients.</p> Methods <p>In this retrospective cross-sectional study, we included EC patients referred to Akbar-Abadi Hospital, Tehran, Iran, from 2011 to 2020, with recorded preoperative serum β-hCG and CA125 levels. Statistical analysis was conducted using SPSS software.</p> Results <p>A total of 93 EC patients were included in the study. The mean age of the patients was 61.93 ± 11.31&#xa0;years. The mean levels of β-hCG and CA125 in EC patients were 2.2 ± 1.19 mIU/mL and 56.72 ± 105.97 U/mL, respectively. Among the patients, 26 (27.9%) exhibited CA125 levels ≥ 35 U/mL, while 25(26.8%) had β-hCG levels exceeding 2&#xa0;mIU/mL, with 17.2% surpassing 4 mIU/mL. Although a significant positive correlation was noted between patients' age and serum β-hCG levels (correlation coefficient = 0.287, <i>p</i> value = 0.005), no significant correlations were observed between serum CA125 and β-hCG levels or between age and CA125 levels.</p> Conclusion <p>The lack of a significant association between CA125 and β-hCG in EC patients suggests that β-hCG may serve as an independent prognostic marker. Further research is needed to explore its correlations with age, survival rate, tumor grade, and disease stage to better understand its role in disease aggressiveness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the Correlation Between β-hCG and CA125 in Patients with Endometrial Cancer: A 10-Year Retrospective Analysis

  • 期刊论文

  • 发表日期：

    2025年1月20日

查看全文
  • Mahdiss Mohamadianamiri,
  • Ainaz Sourati,
  • Sahand Karimzadhagh,
  • Poorya Behnamie,
  • Mohammad Hossain Dadkha,
  • Majid Aklamali

摘要

Background

Endometrial cancer (EC) is the predominant gynecologic malignancy in high-income countries and globally ranks as the sixth most common tumor among women, primarily influenced by hormonal factors. Recent studies have indicated a potential involvement of beta-human chorionic gonadotropin (β-hCG) in EC tumor formation and metastatic progression, expanding its traditional association beyond pregnancy. Hence, our study aimed to examine the levels of β-hCG and their correlation with a well-established tumor marker, cancer antigen (CA) 125, in EC patients.

Methods

In this retrospective cross-sectional study, we included EC patients referred to Akbar-Abadi Hospital, Tehran, Iran, from 2011 to 2020, with recorded preoperative serum β-hCG and CA125 levels. Statistical analysis was conducted using SPSS software.

Results

A total of 93 EC patients were included in the study. The mean age of the patients was 61.93 ± 11.31 years. The mean levels of β-hCG and CA125 in EC patients were 2.2 ± 1.19 mIU/mL and 56.72 ± 105.97 U/mL, respectively. Among the patients, 26 (27.9%) exhibited CA125 levels ≥ 35 U/mL, while 25(26.8%) had β-hCG levels exceeding 2 mIU/mL, with 17.2% surpassing 4 mIU/mL. Although a significant positive correlation was noted between patients' age and serum β-hCG levels (correlation coefficient = 0.287, p value = 0.005), no significant correlations were observed between serum CA125 and β-hCG levels or between age and CA125 levels.

Conclusion

The lack of a significant association between CA125 and β-hCG in EC patients suggests that β-hCG may serve as an independent prognostic marker. Further research is needed to explore its correlations with age, survival rate, tumor grade, and disease stage to better understand its role in disease aggressiveness.